# BPC-157 FAQ — Common Research Questions

> Answers to common questions about BPC-157: mechanism, dosing context, human evidence, WADA status, oral bioavailability, and the state of clinical research. For research purposes only.

## What is BPC-157 and where does it come from?

BPC-157 is a 15-amino-acid synthetic peptide (pentadecapeptide) with the sequence GEPPPGKPADDAGLV and a molecular weight of 1419.5 Da. It is derived from a protein found in human gastric juice — specifically from a body protection compound identified in the stomach's cytoprotective secretions. Its synonyms include Pentadecapeptide BPC 157, PL 14736, and Bepecin. It has no approved human indication anywhere in the world.

## What is the established mechanism of action of BPC-157?

The primary documented mechanism operates through the VEGFR2-Akt-eNOS signaling axis [7, 8, 13]. Activation of this pathway promotes context-appropriate angiogenesis and endothelial nitric oxide production in injured tissue. Alongside this, BPC-157 has been documented to: upregulate growth hormone receptor expression in tendon fibroblasts by up to 7-fold [2]; activate FAK-paxillin signaling to enhance fibroblast migration and collagen deposition [17]; activate ERK1/2 for endothelial proliferation [17]; and modulate NF-kB, dopaminergic, and serotonergic pathways [9, 10]. A 2025 systematic review of 36 studies confirmed VEGFR2-Akt-eNOS, ERK1/2, and FAK-paxillin as the primary pathways in musculoskeletal repair models [17].

## What does the preclinical research show about BPC-157 and tissue repair?

Twenty cataloged preclinical findings span tendon, ligament, muscle, bone, wound/burn, vascular, and neurological injury models. Consistent findings: BPC-157 groups demonstrate faster repair, superior biomechanical outcomes, normalized biochemical injury markers, and reduced macroscopic damage versus saline controls. Notable results include: full Achilles tendon integrity reestablished by day 14 [1]; MCL healing improvement through 90 days [3]; muscle-to-bone reattachment confirmed by MRI at day 21–28 after complete quadriceps detachment [18]; and bone defect healing comparable to autologous graft at 6 weeks in rabbits [6]. Most primary research originates from the Sikiric group at the University of Zagreb; independent replication is limited [17].

## What are the common doses studied in BPC-157 animal research?

The most common intraperitoneal dose ladder in rodent studies uses 10 μg/kg, 10 ng/kg, and 10 pg/kg — spanning a 10,000,000-fold range. Multiple studies show efficacy across the full range, including at the picogram dose [4, 13]. Oral delivery typically uses 10 μg/kg/day and 10 ng/kg/day in drinking water. Topical cream studies use 1 μg/g. No toxic dose has been established up to 20 mg/kg in rats [20].

## Is there any human clinical trial data for BPC-157?

Three published human pilot studies exist as of 2026 [14, 15, 16]. The knee pain study (Lee & Padgett, 2021, n=16) reported 87.5% significant pain relief at 6–12 months [16]. The interstitial cystitis study (Lee et al., 2024, n=12) reported 80–100% symptom resolution at 6 weeks after a single 10 mg intravesical injection [15]. The IV safety pilot (Lee & Burgess, 2025, n=2) reported no adverse events and plasma clearance within 24 hours [14]. None of these are randomized controlled trials.

## What is the half-life and pharmacokinetic profile of BPC-157?

Formal PK characterization (He et al., 2022) [11] documented: elimination half-life less than 30 minutes in both rats and dogs; Cmax at 3–9 minutes post-IM injection; IM bioavailability of 14–19% in rats and 45–51% in dogs; linear dose-proportional kinetics. Despite the short half-life, in vivo tissue repair efficacy in published studies persisted to day 14, 28, and 90.

## Can BPC-157 be taken orally, and does it survive the stomach?

BPC-157 demonstrates documented stability in the gastric acid and peptic environment [20]. Multiple preclinical studies delivered BPC-157 via oral gavage or in drinking water and found results comparable to intraperitoneal injection [3, 18]. However, oral bioavailability has not been formally quantified by pharmacokinetic AUC methods.

## What is BPC-157's WADA status?

BPC-157 is prohibited by the World Anti-Doping Agency under the S0 category — Non-Approved Substances. This prohibition applies at all times: in-competition and out-of-competition. No Therapeutic Use Exemption pathway exists. In 2024, an American speed skater received a 1-year sanction following BPC-157 product use. The compound is also listed on the DoD Prohibited Dietary Supplement Ingredients List.

## What tissues and organ systems have been studied with BPC-157?

The published preclinical literature spans six primary tissue and organ categories: musculoskeletal (tendon [1, 2], ligament [3], muscle [5, 18], bone [6]); gastrointestinal mucosal [4]; vascular and endothelial [8, 12]; wound healing [4]; neurological [9, 10]; and angiogenic regulation [7, 13].

## What are the open questions and limitations of BPC-157 research?

Key gaps identified by the 2026 Yuan et al. review [21] and 2025 Vasireddi et al. systematic review [17]: (1) No RCTs in humans; only three small unblinded pilots. (2) Most preclinical research from one group (Sikiric et al., Zagreb); limited independent replication. (3) Oral bioavailability lacks formal PK quantification. (4) Short plasma half-life raises questions about dosing frequency. (5) Potential angiogenic promotion of tumor vascularization has been raised but not specifically studied. (6) Purity and stability of research-grade preparations can vary.

## What is BPC-157's regulatory status globally?

No approved human indication exists in the US, EU, or any other major regulatory jurisdiction. No active IND application is on file with the FDA. One Phase I trial registration (NCT02637284) was listed in 2015 but not completed. BPC-157 is classified as a research chemical and is not approved for prescription, dispensing, or human consumption.

## References

[1] Staresinic M et al. Journal of Orthopaedic Research. 2003. DOI: 10.1016/S0736-0266(03)00110-4
[2] Chang CH et al. Molecules. 2014;19(11):19066-19077.
[3] Cerovecki T et al. Journal of Orthopaedic Research. 2010. DOI: 10.1002/jor.21107
[4] Seiwerth S et al. Frontiers in Pharmacology. 2021. DOI: 10.3389/fphar.2021.627533
[5] Novinscak T et al. Surgery Today. 2008. DOI: 10.1007/s00595-007-3706-2
[6] Sebecic B et al. Bone. 1999. DOI: 10.1016/s8756-3282(98)00180-x
[7] Brcic L et al. Journal of Physiology and Pharmacology. 2009. PMID: 20388964
[8] Sikiric P et al. World Journal of Gastroenterology. 2022. DOI: 10.3748/wjg.v28.i1.23
[9] Sikiric P et al. Pharmaceuticals (Basel). 2024;17(4):461.
[10] Sikiric P et al. Pharmaceuticals (Basel). 2024;17(4):461.
[11] He L et al. Frontiers in Pharmacology. 2022. DOI: 10.3389/fphar.2022.1026182
[12] Tepes M et al. Pharmaceuticals (Basel). 2023. DOI: 10.3390/ph16111554
[13] Sikiric P et al. Pharmaceuticals (Basel). 2025;18(6):928.
[14] Lee E, Burgess K. Alternative Therapies in Health and Medicine. 2025. PMID: 40131143
[15] Lee E, Walker C, Ayadi B. Alternative Therapies in Health and Medicine. 2024.
[16] Lee E, Padgett B. Alternative Therapies in Health and Medicine. 2021. PMID: 33609460
[17] Vasireddi N et al. HSS Journal. 2025. DOI: 10.1177/15563316251355551
[18] Matek D et al. Pharmaceutics. 2025;17(1):119.
[20] Jozwiak M et al. Pharmaceuticals (Basel). 2025;18(2):185.
[21] Yuan C et al. International Journal of Molecular Sciences. 2026;27(6):2876.

---

For research purposes only. Not for human consumption. This site does not sell any product and is not affiliated with any vendor.